Search Results - "Miskin, Hari P"

G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy by Ribeiro, Marcelo Lima, Profitós-Pelejà, Núria, Santos, Juliana Carvalho, Blecua, Pedro, Reyes-Garau, Diana, Armengol, Marc, Fernández-Serrano, Miranda, Miskin, Hari P, Bosch, Francesc, Esteller, Manel, Normant, Emmanuel, Roué, Gael

“…Immunotherapy-based regimens have considerably improved the survival rate of B-cell non-Hodgkin lymphoma (B-NHL) patients in the last decades; however, most…”
Get full text

Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis by Alvarez, Enrique, Steinman, Lawrence, Fox, Edward J., Hartung, Hans-Peter, Qian, Peiqing, Wray, Sibyl, Robertson, Derrick, Selmaj, Krzysztof, Wynn, Daniel, Mok, Koby, Xu, Yihuan, Bodhinathan, Karthik, Miskin, Hari P., Cree, Bruce A. C.

“…Background Ublituximab is a novel anti-CD20 monoclonal antibody glycoengineered for enhanced antibody-dependent cellular cytotoxicity. The phase 3 ULTIMATE I…”
Get full text

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study by Burris, Howard A, Flinn, Ian W, Patel, Manish R, Fenske, Timothy S, Deng, Changchun, Brander, Danielle M, Gutierrez, Martin, Essell, James H, Kuhn, John G, Miskin, Hari P, Sportelli, Peter, Weiss, Michael S, Vakkalanka, Swaroop, Savona, Michael R, O'Connor, Owen A

“…Umbralisib (TGR-1202) is a novel next-generation inhibitor of phosphatidylinositol 3-kinase (PI3K) isoform p110δ (PI3Kδ), which is structurally distinct from…”
Get full text

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis by Steinman, Lawrence, Fox, Edward, Hartung, Hans-Peter, Alvarez, Enrique, Qian, Peiqing, Wray, Sibyl, Robertson, Derrick, Huang, DeRen, Selmaj, Krzysztof, Wynn, Daniel, Cutter, Gary, Mok, Koby, Hsu, Yanzhi, Xu, Yihuan, Weiss, Michael S., Bosco, Jenna A., Power, Sean A., Lee, Lily, Miskin, Hari P., Cree, Bruce A.C.

“…In two parallel randomized trials in patients with MS, ublituximab resulted in lower relapse rates and fewer brain lesions on MRI than teriflunomide over a…”
Get full text

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia by Lunning, Matthew, Vose, Julie, Nastoupil, Loretta, Fowler, Nathan, Burger, Jan A., Wierda, William G., Schreeder, Marshall T., Siddiqi, Tanya, Flowers, Christopher R., Cohen, Jonathon B., Sportelli, Peter, Miskin, Hari P., Weiss, Michael S., O'Brien, Susan

“…Targeting both CD20 and phosphatidylinositol 3-kinase (PI3K), a protein that is critically involved in B-cell maturation, could be an efficacious strategy for…”
Get full text

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma by Fowler, Nathan H, Samaniego, Felipe, Jurczak, Wojciech, Ghosh, Nilanjan, Derenzini, Enrico, Reeves, James A, Knopińska-Posłuszny, Wanda, Cheah, Chan Y, Phillips, Tycel, Lech-Maranda, Ewa, Cheson, Bruce D, Caimi, Paolo F, Grosicki, Sebastian, Leslie, Lori A, Chavez, Julio C, Fonseca, Gustavo, Babu, Sunil, Hodson, Daniel J, Shao, Spencer H, Burke, John M, Sharman, Jeff P, Law, Jennie Y, Pagel, John M, Miskin, Hari P, Sportelli, Peter, O'Connor, Owen A, Weiss, Michael S, Zinzani, Pier Luigi

“…Phosphatidylinositol-3-kinase (PI3K) inhibitors have shown activity in relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). PI3K inhibitors have…”
Get full text

A phase 1/2 trial of ublituximab, a novel anti‐CD20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab by Sawas, Ahmed, Farber, Charles M., Schreeder, Marshall T., Khalil, Mazen Y., Mahadevan, Daruka, Deng, Changchun, Amengual, Jennifer E., Nikolinakos, Petros G., Kolesar, Jill M., Kuhn, John G., Sportelli, Peter, Miskin, Hari P., O'Connor, Owen A.

“…Summary This phase 1/2 study evaluated the safety, pharmacokinetic behavior and anti‐tumour activity of ublituximab, a unique type I, chimeric, glycoengineered…”
Get full text

Ublituximab (TG‐1101), a novel glycoengineered anti‐CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial by Sharman, Jeff P., Farber, Charles M., Mahadevan, Daruka, Schreeder, Marshall T., Brooks, Heather D., Kolibaba, Kathryn S., Fanning, Suzanne, Klein, Leonard, Greenwald, Daniel R., Sportelli, Peter, Miskin, Hari P., Weiss, Michael S., Burke, John M.

“…Summary Ibrutinib is effective in patients with chronic lymphocytic leukaemia (CLL); however, treatment resistance remains a problem. Ublituximab is a novel,…”
Get full text

Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy by Mato, Anthony R., Ghosh, Nilanjan, Schuster, Stephen J., Lamanna, Nicole, Pagel, John M., Flinn, Ian W., Barrientos, Jacqueline C., Rai, Kanti R., Reeves, James A., Cheson, Bruce D., Barr, Paul M., Kambhampati, Suman, Lansigan, Frederick, Pu, Jeffrey J., Skarbnik, Alan P., Roeker, Lindsey, Fonseca, Gustavo A., Sitlinger, Andrea, Hamadeh, Issam S., Dorsey, Colleen, LaRatta, Nicole, Weissbrot, Hanna, Luning Prak, Eline T., Tsao, Patricia, Paskalis, Dana, Sportelli, Peter, Miskin, Hari P., Weiss, Michael S., Svoboda, Jakub, Brander, Danielle M.

“…Intolerance is the most common reason for kinase inhibitor (KI) discontinuation in chronic lymphocytic leukemia (CLL). Umbralisib, a novel highly selective…”
Get full text

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia by Hill, Brian T, Ma, Shuo, Zent, Clive S, Baran, Andrea M, Wallace, Danielle S, Advani, Anjali, Winter, Allison, Winter, Jane, Gordan, Leo, Karmali, Reem, Liesveld, Jane L, Mulford, Deborah A, Rowland, Chris, Bui, Andrew, Sportelli, Peter, Miskin, Hari P, Weiss, Michael S, Friedberg, Jonathan W, Barr, Paul M

“…Many patients with chronic lymphocytic leukemia (CLL) will develop treatment resistance to Bruton tyrosine kinase (BTK) inhibitors…”
Get full text

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study by Davids, Matthew S, Kim, Haesook T, Nicotra, Alyssa, Savell, Alexandra, Francoeur, Karen, Hellman, Jeffrey M, Bazemore, Josie, Miskin, Hari P, Sportelli, Peter, Stampleman, Laura, Maegawa, Rodrigo, Rueter, Jens, Boruchov, Adam M, Arnason, Jon E, Jacobson, Caron A, Jacobsen, Eric D, Fisher, David C, Brown, Jennifer R

“…Patients with relapsed or refractory high-risk chronic lymphocytic leukaemia or mantle cell lymphoma often do not derive durable benefit from ibrutinib…”
Get full text

Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach by Roeker, Lindsey E, Feldman, Tatyana A, Soumerai, Jacob D, Falco, Victoria, Panton, Gail, Dorsey, Colleen, Zelenetz, Andrew D, Falchi, Lorenzo, Park, Jae H, Straus, David J, Pena Velasquez, Camila, Lebowitz, Sonia, Fox, Yehudit, Battiato, Kristen, Laudati, Carissa, Thompson, Meghan C, McCarthy, Elizabeth, Kdiry, Sabrina, Martignetti, Rosalba, Turpuseema, Teja, Purdom, Michelle, Paskalis, Dana, Miskin, Hari P, Sportelli, Peter, Leslie, Lori A, Mato, Anthony R

“…Ibrutinib has transformed the management of chronic lymphocytic leukemia (CLL), though its use is limited by toxicity and resistance. In this study, we…”
Get full text

The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells by Maharaj, Kamira, Powers, John J., Achille, Alex, Mediavilla-Varela, Melanie, Gamal, Wael, Burger, Karen L., Fonseca, Renee, Jiang, Kun, Miskin, Hari P., Maryanski, Dave, Monastyrskyi, Andrii, Duckett, Derek R., Roush, William R., Cleveland, John L., Sahakian, Eva, Pinilla-Ibarz, Javier

“…The in-clinic phosphatidylinositol 3-kinase (PI3K) inhibitors idelalisib (CAL-101) and duvelisib (IPI-145) have demonstrated high rates of response and…”
Get full text

Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma by Wallace, Danielle S., Rowland, Chris, Hill, Brian T., Baran, Andrea M., Casulo, Carla, Reagan, Patrick M., Winter, Allison, Karmali, Reem, Winter, Jane N., Gordon, Leo I., Bui, Andrew, Sportelli, Peter, Miskin, Hari P., Weiss, Michael S., Friedberg, Jonathan W., Ma, Shuo, Barr, Paul M.

Get full text

Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial by Nastoupil, Loretta J, Lunning, Matthew A, Vose, Julie M, Schreeder, Marshall T, Siddiqi, Tanya, Flowers, Christopher R, Cohen, Jonathon B, Burger, Jan A, Wierda, William G, O'Brien, Susan, Sportelli, Peter, Miskin, Hari P, Purdom, Michelle A, Weiss, Michael S, Fowler, Nathan H

“…Therapeutic approaches for B-cell malignancies continue to evolve, especially with regard to combination approaches. We assessed the safety and efficacy of the…”
Get full text

Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial by Sharman, Jeff P, Brander, Danielle M, Mato, Anthony R, Ghosh, Nilanjan, Schuster, Stephen J, Kambhampati, Suman, Burke, John M, Lansigan, Frederick, Schreeder, Marshall T, Lunin, Scott D, Zweibach, Alexander, Shtivelband, Mikhail, Travis, Patrick M, Chandler, Jason C, Kolibaba, Kathryn S, Sportelli, Peter, Miskin, Hari P, Weiss, Michael S, Flinn, Ian W

“…Patients with chronic lymphocytic leukaemia and high-risk features have poorer outcomes on ibrutinib than those without high-risk features. The aim of this…”
Get full text

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies by Davids, Matthew S., O'Connor, Owen A., Jurczak, Wojciech, Samaniego, Felipe, Fenske, Timothy S., Zinzani, Pier Luigi, Patel, Manish R., Ghosh, Nilanjan, Cheson, Bruce D., Derenzini, Enrico, Brander, Danielle M., Reeves, James A., Knopińska-Posłuszny, Wanda, Allan, John N., Phillips, Tycel, Caimi, Paolo F., Lech-Maranda, Ewa, Burke, John M., Agajanian, Richy, Pettengell, Ruth, Leslie, Lori A., Cheah, Chan Y., Fonseca, Gustavo, Essell, James, Chavez, Julio C., Pagel, John M., Sharman, Jeff P., Hsu, Yanzhi, Miskin, Hari P., Sportelli, Peter, Weiss, Michael S., Flinn, Ian W.

“…Phosphoinositide 3-kinase-δ (PI3Kδ) inhibitors are active in lymphoid malignancies, although associated toxicities can limit their use. Umbralisib is a dual…”
Get full text

A Phase II Trial of Acalabrutinib in Combination with PI3Kδ Inhibitor Umbralisib and the Anti-CD20 Antibody Ublituximab (AU2) in Patients with Previously Untreated Mantle Cell Lymphoma (MCL) by Danilov, Alexey V, Muir, Alexandra, Melgar, Ivana, Puverel, Sandrine, Sportelli, Peter, Miskin, Hari P., Chen, Lu, Shouse, Geoffrey

Get full text

First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients (pts) with B-Cell Lymphoma by Hawkes, Eliza, Lewis, Katharine L., Wong Doo, Nicole, Patil, Sushrut S., Miskin, Hari P., Sportelli, Peter, Kolibaba, Kathryn S., Normant, Emmanuel, Turpuseema, Tejasvi, Cheah, Chan Y.

Get full text

The Ublituximab-Umbralisib (U2) Drug Regimen Potentiates the Activity of the Novel CD47-CD19 Bispecific Antibody, TG-1801, through the Activation of the G Protein-Coupled Receptor EBI2/GPR183 by Normant, Emmanuel, Ribeiro, Marcelo Lima, Profitos-Peleja, Nuria, Blecua, Pedro, Reyes-Garau, Diana, Santos, Juliana Carvalho, Armengol, Marc, Fernández-Serrano, Miranda, Miskin, Hari P., Roue, Gael

“…Introduction: TG-1801 is a novel, bispecific anti-CD47 and anti-CD19 fully human IgG1 antibody that targets CD47 selectively on CD19+ B-cells, sparing red…”
Get full text